In last trading session, Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) saw 1.65 million shares changing hands with its beta currently measuring 0.35. Company’s recent per share price level of $0.41 trading at $0.0 or 1.02% at ring of the bell on the day assigns it a market valuation of $2.61M. That closing price of CYCC’s stock is at a discount of -875.61% from its 52-week high price of $4.00 and is indicating a premium of 24.39% from its 52-week low price of $0.31. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 12.3 million shares which gives us an average trading volume of 3.52 million if we extend that period to 3-months.
For Cyclacel Pharmaceuticals Inc (CYCC), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) trade information
Upright in the green during last session for gaining 1.02%, in the last five days CYCC remained trading in the green while hitting it’s week-highest on Friday, 01/03/25 when the stock touched $0.41 price level, adding 53.93% to its value on the day. Cyclacel Pharmaceuticals Inc’s shares saw a change of 10.35% in year-to-date performance and have moved 10.35% in past 5-day. Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) showed a performance of 10.05% in past 30-days. Number of shares sold short was 66765.0 shares which calculate 0.03 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 1 to the stock, which implies a rise of 59.0% to its current value. Analysts have been projecting 1 as a low price target for the stock while placing it at a high target of 1. It follows that stock’s current price would drop -143.9% in reaching the projected high whereas dropping to the targeted low would mean a loss of -143.9% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 32.13% during past 5 years.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)’s Major holders
Insiders are in possession of 4.82% of company’s total shares while institution are holding 18.03 percent of that, with stock having share float percentage of 18.94%. Investors also watch the number of corporate investors in a company very closely, which is 18.03% institutions for Cyclacel Pharmaceuticals Inc that are currently holding shares of the company.
